货号:A878035 同义名: 利福布丁 / Ansamycin;LM-427
Rifabutin is an antibiotic used to treat tuberculosis and prevent and treat Mycobacterium avium complex, which works through inhibiting DNA-dependent RNA polymerase activity in susceptible cells.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | Rifabutin (RBT) is the rifamycin that is recommended to treat tuberculosis (TB) in HIV-infected individuals during combination antiretroviral therapy (ART) containing HIV protease inhibitors (PIs)[3]. Rifabutin is a rifamycin with activity against Mycobacterium tuberculosis. RFB is well tolerated by patients who develop RMP-related (Rifampin) AEs (adverse effects)[4]. Rifabutin at 16 μg/mL was only bacteriostatic (MIC of 4 μg/mL) and was moderately synergistic in combination with imipenem (fractional inhibitory concentration [FIC] index of 0.38). Addition of rifabutin (16 μg/mL) moderately increased killing by a low (8 μg/mL) but not by a high (32 μg/mL) concentration of imipenem. In infected macrophages, rifabutin (16 μg/mL) increased the activity of imipenem at 8 and 32 μg/mL, achieving 3- and 100-fold reductions in the numbers of intracellular bacteria, respectively[5]. The use of rifabutin can improve treatment outcomes in patients with rifabutin-sensitive MDR-TB[6]. In addition, the combination of rifabutin plus bedaquiline produces sustained intracellular mycobactericidal activity that is greater than the sum of their individual effects[7]. |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT02024555 | Sarcoidosis; Antimycobacterial... 展开 >> Therapy 收起 << | Phase 2 | Recruiting | May 2019 | United States, New York ... 展开 >> Albany Medical Center Recruiting Albany, New York, United States, 12208 Contact: Marc Judson, MD 518-262-5196 judsonm@mail.amc.edu Contact: Leahruth Saavedra, MS (518) 262-0355 saavedl@amc.edu Sub-Investigator: Marc Judson, MD United States, Ohio University of Cincinnati Recruiting Cincinnati, Ohio, United States, 45267 Contact: Robert Baughman, MD 513-584-5110 bob.baughman@ucmail.uc.edu Contact: Joyce Zeigler (513) 584-6252 zeiglejm@ucmail.uc.edu Principal Investigator: Robert Baughman, MD Cleveland Clinic Recruiting Cleveland, Ohio, United States, 44195 Contact: Dan Culver, DO 216-444-6508 culverd@ccf.org Contact: Allison Wimer 216-444-9975 wimera@ccf.org Principal Investigator: Dan Culver, DO Ohio State University Recruiting Columbus, Ohio, United States, 43221 Contact: Elliott Crouser, M.D. 614-293-4925 elliott.crouser@osumc.edu Contact: Karen Martin 614-293-4978 karen.martin@osumc.edu Sub-Investigator: Elliott Crouser, M.D. United States, South Carolina Medical University of South Carolina Recruiting Charleston, South Carolina, United States, 29425 Contact: Ennis James, MD 843-792-3769 jamesw@musc.edu Contact: Robyn Do (843) 792-1221 dorobyn@musc.edu Sub-Investigator: Ennis James, MD United States, Tennessee Vanderbilt University School of Medicine Recruiting Nashville, Tennessee, United States, 37232 Contact: Wonder Drake, MD 615-322-2035 wonder.drake@vanderbilt.edu Contact: Amy Kerrigan, MSN 615-343-3238 amy.kerrigan@vanderbilt.edu Principal Investigator: Wonder Drake, MD 收起 << |
NCT02099240 | Osteomyelitis | Early Phase 1 | Recruiting | September 2019 | United States, Kentucky ... 展开 >> University of Louisville Recruiting Louisville, Kentucky, United States, 40202 Contact: Julio A Ramirez, MD 502-852-1148 jarami01@louisville.edu Contact: David Seligson, MD 502-852-0923 d0seli01@louisville.edu Sub-Investigator: Forest Arnold, DO Sub-Investigator: Timothy Wiemkwn, PhD Sub-Investigator: Robert Kelley, PhD Sub-Investigator: James Summersgill, PhD Sub-Investigator: Ruth Carrico, PhD Sub-Investigator: Julie Harting, PharmD Sub-Investigator: Paula Peyrani, MD Principal Investigator: David Seligson, MD Sub-Investigator: Craig Roberts, MD Principal Investigator: Julio Ramirez, MD 收起 << |
NCT01951326 | Crohn's Disease | Phase 3 | Active, not recruiting | April 2019 | - |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.18mL 0.24mL 0.12mL |
5.90mL 1.18mL 0.59mL |
11.81mL 2.36mL 1.18mL |
CAS号 | 72559-06-9 |
分子式 | C46H62N4O11 |
分子量 | 847.005 |
别名 | 利福布丁 ;Ansamycin;LM-427;Rifabutina;Mycobutin |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Keep in dark place,Inert atmosphere,Store in freezer, under -20°C |
溶解度 |
DMSO: 50 mg/mL(59.03 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |